ReviewJournal of molecular modeling2026
Molecular docking: a computational approach for the discovery of novel targets against visceral leishmaniasis.
Review in Journal of molecular modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Towards precision antileishmanial drug discovery: Integrating multi-omics, functional genomics, artificial intelligence and host-directed therapeutics.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextThe protozoan parasite Leishmania donovani is a major causative agent of visceral leishmaniasis (VL), a lethal disease posing significant public health challenges globally. Existing anti-VL drugs have become increasingly ineffective due to rising drug resistance, underscoring the urgent need for novel and effective therapeutic candidates. Computational approaches offer rapid and systematic methods for identifying potential drug targets and supporting rational drug design. This review discusses in silico molecular docking studies targeting various Leishmania proteins and their inhibitors, alongside the in vitro and in vivo validation of selected compounds, emphasizing their crucial roles in advancing antileishmanial drug discovery.
methodsIn the review, we have focused on a molecular docking study and explored potential compounds with high binding energy toward protein targets of Leishmania. Following the in silico screening, our review highlights compounds that exhibit both in vitro and in vivo antileishmanial properties, allowing for an assessment of their therapeutic efficacy. Different Software is available for molecular docking, has been mentioned in the review. Overall conclusion of this review supports the computational approach in drug discovery before the in vitro and in vivo study, which can save cost and time efficiency as well.
Indexed as
Identifiers
41701359What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.